Press Releases + New Year: - Any -2024202320222021202020192018201720162015201420132012201120102009 Items per page 102550 Date Title and Summary View Toggle SummaryJan 15, 2013 Galectin Therapeutics Appoints Industry Veteran Rex Horton as Executive Director of Regulatory Affairs and Quality Assurance View HTML Galectin Therapeutics Appoints Industry Veteran Rex Horton as Executive Director of Regulatory Affairs and Quality Assurance 16.6 KB Toggle SummaryNov 26, 2012 Galectin Therapeutics Receives US Patent for Second Drug Class to Treat Chronic Liver Disease with Fibrosis (Scarring) and Cirrhosis View HTML Galectin Therapeutics Receives US Patent for Second Drug Class to Treat Chronic Liver Disease with Fibrosis (Scarring) and Cirrhosis 16.1 KB Toggle SummaryNov 12, 2012 Galectin Therapeutics Presents New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012 View HTML Galectin Therapeutics Presents New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012 15.9 KB Toggle SummaryNov 09, 2012 Galectin Therapeutics Reports Third Quarter 2012 Financial Results View HTML Galectin Therapeutics Reports Third Quarter 2012 Financial Results 19.4 KB Toggle SummaryOct 26, 2012 Galectin Therapeutics to Present New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012 View HTML Galectin Therapeutics to Present New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012 15.5 KB Toggle SummarySep 20, 2012 Galectin Therapeutics Hosted International Conference on Galectins and Disease --Proceedings from the Conference to be Published in Early 2013-- View HTML Galectin Therapeutics Hosted International Conference on Galectins and Disease 14.7 KB Toggle SummaryAug 31, 2012 Galectin Therapeutics Announces Relocation of Corporate Headquarters to Atlanta, GA View HTML Galectin Therapeutics Announces Relocation of Corporate Headquarters to Atlanta, GA 15.5 KB Toggle SummaryAug 29, 2012 Galectin Therapeutics Appoints Harold H. Shlevin, PhD, Bioscience Industry Executive, as Chief Operating Officer View HTML Galectin Therapeutics Appoints Harold H. Shlevin, PhD, Bioscience Industry Executive, as Chief Operating Officer 16.9 KB Toggle SummaryAug 23, 2012 Galectin Therapeutics to Present at the RedChip Small-Cap Equities Virtual Conference View HTML Galectin Therapeutics to Present at the RedChip Small-Cap Equities Virtual Conference 13.8 KB Toggle SummaryAug 10, 2012 Galectin Therapeutics Reports Second Quarter 2012 Financial Results View HTML Galectin Therapeutics Reports Second Quarter 2012 Financial Results 19.3 KB Pagination First page First Previous page Previous … Page 28 Current page 29 Page 30 Page 31 … Next page Next Last page Last
Galectin Therapeutics Appoints Industry Veteran Rex Horton as Executive Director of Regulatory Affairs and Quality Assurance 16.6 KB
Galectin Therapeutics Receives US Patent for Second Drug Class to Treat Chronic Liver Disease with Fibrosis (Scarring) and Cirrhosis 16.1 KB
Galectin Therapeutics Presents New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012 15.9 KB
Galectin Therapeutics to Present New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012 15.5 KB
Galectin Therapeutics Appoints Harold H. Shlevin, PhD, Bioscience Industry Executive, as Chief Operating Officer 16.9 KB
